Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026

Perrigo (PRGO)

NYSE Health Care Pharmaceuticals S&P SmallCap 600
$15.85
+0.14 (+0.89%)
Close of Nov 06, 2026 · end-of-day data
Source: Perrigo's 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 05, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$5.28B$4.95B$4.73B$3.87B$4.09B$4.14B$4.45B$4.66B$4.37B$4.25B
Cost of revenue$3.23B$2.97B$2.90B$2.44B$2.59B$2.72B$3.00B$2.98B$2.83B$2.76B
Gross profit$2.05B$1.98B$1.83B$1.43B$1.49B$1.42B$1.46B$1.68B$1.54B$1.49B
Research & development$184.00M$167.70M$218.60M$119.20M$121.70M$122.00M$123.10M$122.50M$112.20M$95.40M
Operating income-$2.00B$598.20M$236.50M$174.70M$265.20M$410.40M$78.90M$151.90M$112.90M-$1.12B
Pre-tax income-$4.85B$280.10M$290.60M——$258.70M-$139.10M-$8.30M-$80.70M-$1.30B
Income tax-$835.50M$160.50M$159.60M-$10.70M-$38.30M$389.60M-$8.20M-$3.90M$80.00M$104.40M
Net income-$4.01B$119.60M$131.00M$146.10M-$162.60M-$68.90M-$140.60M-$12.70M-$171.80M-$1.43B
EBITDA-$1.54B$1.04B$660.10M$571.20M$650.00M$722.60M$417.50M$511.40M$438.80M-$784.70M
EPS (basic)$-28.01$0.84$0.95$1.07$-1.20$-0.52$-1.04$-0.09$-1.25$-10.29
EPS (diluted)$-28.01$0.84$0.95$1.07$-1.19$-0.52$-1.04$-0.09$-1.25$-10.29
Diluted shares143.30M142.60M138.30M136.50M137.20M133.60M134.50M135.30M137.40M138.50M
Gross margin38.9%40.0%38.7%37.0%36.6%34.2%32.7%36.1%35.3%35.1%
Operating margin-37.9%12.1%5.0%4.5%6.5%9.9%1.8%3.3%2.6%-26.4%
Net margin-76.0%2.4%2.8%3.8%-4.0%-1.7%-3.2%-0.3%-3.9%-33.5%

Balance sheet

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$622.30M$678.70M$551.10M$354.30M$631.50M$1.86B$600.70M$751.30M$558.80M$531.60M
Receivables$1.18B$1.13B$1.07B$1.24B$593.50M$652.90M$697.10M$739.60M$642.30M$612.80M
Inventory$795.00M$806.90M$878.00M$967.30M$1.06B$1.02B$1.15B$1.14B$1.08B$1.15B
Total current assets$2.81B$2.82B$2.90B$2.73B$3.13B$3.86B$2.72B$2.83B$2.48B$2.80B
Goodwill$4.05B$4.18B$3.98B$3.10B$3.10B$3.00B$3.49B$3.53B$3.32B$2.05B
Total assets$13.87B$11.63B$10.98B$11.30B$11.49B$10.43B$11.02B$10.81B$9.65B$8.54B
Total current liabilities$1.84B$1.44B$1.54B$1.34B$1.38B$1.59B$1.11B$1.59B$1.04B$1.01B
Short-term debt$572.80M$70.40M$190.20M$3.40M$37.30M$603.80M$36.20M$440.60M$36.40M$36.60M
Long-term debt$5.22B$3.27B$3.05B$3.37B$3.53B$2.92B$4.07B$3.63B$3.58B$3.60B
Total debt$5.80B$3.34B$3.24B$3.37B$3.56B$3.52B$4.11B$4.07B$3.62B$3.64B
Total liabilities$7.91B$5.46B$5.32B$5.50B$5.83B$5.27B$6.18B$6.04B$5.33B$5.60B
Shareholders' equity$5.96B$6.17B$5.67B$5.80B$5.66B$5.15B$4.84B$4.77B$4.32B$2.94B

Cash flow

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow$654.90M$698.90M$593.00M$387.80M$636.20M$156.30M$307.30M$405.50M$362.90M$238.50M
Capital expenditures$106.20M$88.60M$102.60M$137.70M$170.40M$152.10M$96.40M$101.70M$118.30M$93.40M
Free cash flow$548.70M$610.30M$490.40M$250.10M$465.80M$4.20M$210.90M$303.80M$244.60M$145.10M
Investing cash flow-$175.00M$2.34B-$126.80M-$596.10M-$187.80M$1.28B-$1.96B-$77.50M$78.80M-$75.40M
Financing cash flow-$268.70M-$3.00B-$571.90M$1.80M-$181.10M-$178.70M$421.60M-$187.20M-$611.00M-$220.50M
Dividends paid$83.20M$91.10M$104.90M$112.40M$123.90M$129.60M$142.40M$149.70M$152.50M$159.30M
Share buybacks$0$191.50M$400.00M$0$164.20M$0$0———
Stock-based compensation$23.00M$43.80M$37.70M$52.20M$58.50M$60.10M$54.90M$68.80M$64.40M$54.60M
Depreciation & amortization$457.00M$444.80M$423.60M$396.50M$384.80M$312.20M$338.60M$359.50M$325.90M$337.50M

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.